Under the deal, Hims & Hers will offer patients access to FDA-approved versions of Ozempic and Wegovy at the same self-pay prices available through other telehealth platforms
Starting January 1, 2027, Lilly’s Zepbound (tirzepatide), Mounjaro (tirzepatide), and orforglipron, if approved, will be available through participating Medicare Part D plans
The company says those insights can power advanced analytics and real-world evidence (RWE), helping researchers improve trial design, study feasibility, and recruitment strategies
The company announced positive topline data from the Phase II ZUPREME-1 trial
The licensed intellectual property covers methods and designs for CAR constructs engineered to function in myeloid cell populations
Moderna will appeal to the Federal Circuit to assert that its government-contractor immunity limits liability under federal law
Merck emphasized the broader significance of the findings
This study evaluated a difficult-to-treat Crohn's disease patient population
Our clinical data suggests ProLectin-M demonstrated earlier reductions in viral shedding compared with placebo with a favorable safety profile
Subscribe To Our Newsletter & Stay Updated
